Direct seller Medifast (MED -4%) trades down after its Q3 misses the mark. Revenue from its...

|By:, SA News Editor

Direct seller Medifast (MED -4%) trades down after its Q3 misses the mark. Revenue from its direct selling channel increased 6% Y/Y, as its bottom line suffered from higher training costs and a lower average revenue per health coach per month. Separately, Northland Securities and Janney Capital downgrade the stock on the poor results.